Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the ...
Zacks.com on MSN5d
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EUPfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to ...
GlobalData on MSN5d
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophiliaThe European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI ...
Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The ...
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...
(RTTNews) - Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI (marstacimab) to treat adults and adolescents with ...
HYMPAVZI is a once-weekly subcutaneous treatment option for individuals with severe haemophilia A or B. Credit: Andrey_Popov/Shutterstock. The European Commission (EC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback